Skip to main content
Premium Trial:

Request an Annual Quote

Tekmira Starts Phase I Study of Ebola Treatment

Premium

Tekmira Pharmaceuticals said this week that it has begun enrolling patients in a phase I trial of its Ebola virus infection treatment TKM-Ebola.

The 56-patient, placebo-controlled study has two arms. The first will test single ascending doses of the siRNA-based drug in up to six cohorts of four patients each. The second arm will examine multiple ascending doses in three four-patient cohorts.

TKM-Ebola is being developed with the support of a $140 million contract from the US government. In 2010, Tekmira showed that a cocktail of modified siRNAs targeting the Zaire Ebola virus L polymerase, viral protein 24, and viral protein 35 could completely protect non-human primates from a lethal dose of the virus when delivered using proprietary lipid nanoparticles (GSN 8/9/2010).

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.